Terms: = Bone cancer AND IDH1, IDP, 3417, ENSG00000138413, IDH, PICD, O75874 AND Treatment
95 results:
1. A personalized medicine approach identifies enasidenib as an efficient treatment for idh2 mutant chondrosarcoma.
Rey V; Tornín J; Alba-Linares JJ; Robledo C; Murillo D; Rodríguez A; Gallego B; Huergo C; Viera C; Braña A; Astudillo A; Heymann D; Szuhai K; Bovée JVMG; Fernández AF; Fraga MF; Alonso J; Rodríguez R
EBioMedicine; 2024 Apr; 102():105090. PubMed ID: 38547578
[TBL] [Abstract] [Full Text] [Related]
2. Targeted single-cell RNA sequencing analysis reveals metabolic reprogramming and the ferroptosis-resistant state in hematologic malignancies.
Shen X; Dong P; Kong J; Sun N; Wang F; Sang L; Xu Y; Zhang M; Chen X; Guo R; Wang S; Lin Q; Jiang Z; Xu S; Zhang C; Bian Z; Wang W; Guo R
Cell Biochem Funct; 2023 Dec; 41(8):1343-1356. PubMed ID: 37823726
[TBL] [Abstract] [Full Text] [Related]
3. Oncometabolite D-2-hydroxyglutarate-dependent metabolic reprogramming induces skeletal muscle atrophy during cancer cachexia.
Zhu X; Hao J; Zhang H; Chi M; Wang Y; Huang J; Xu R; Xincai Z; Xin B; Sun X; Zhang J; Zhou S; Cheng D; Yuan T; Ding J; Zheng S; Guo C; Yang Q
Commun Biol; 2023 Sep; 6(1):977. PubMed ID: 37741882
[TBL] [Abstract] [Full Text] [Related]
4. Blast phase myeloproliferative neoplasm: contemporary review and 2024 treatment algorithm.
Tefferi A; Alkhateeb H; Gangat N
Blood Cancer J; 2023 Jul; 13(1):108. PubMed ID: 37460550
[TBL] [Abstract] [Full Text] [Related]
5. A Direct Comparison, and Prioritisation, of the Immunotherapeutic Targets Expressed by Adult and Paediatric Acute Myeloid Leukaemia Cells: A Systematic Review and Meta-Analysis.
Morris VS; Ghazi H; Fletcher DM; Guinn BA
Int J Mol Sci; 2023 Jun; 24(11):. PubMed ID: 37298623
[TBL] [Abstract] [Full Text] [Related]
6. Preclinical Characterization and Phase I Trial Results of INBRX-109, A Third-Generation, Recombinant, Humanized, Death Receptor 5 Agonist Antibody, in Chondrosarcoma.
Subbiah V; Chawla SP; Conley AP; Wilky BA; Tolcher A; Lakhani NJ; Berz D; Andrianov V; Crago W; Holcomb M; Hussain A; Veldstra C; Kalabus J; O'Neill B; Senne L; Rowell E; Heidt AB; Willis KM; Eckelman BP
Clin Cancer Res; 2023 Aug; 29(16):2988-3003. PubMed ID: 37265425
[TBL] [Abstract] [Full Text] [Related]
7. Therapies for acute myeloid leukemia in patients ineligible for standard induction chemotherapy: a systematic review.
Heuser M; Fernandez C; Hauch O; Klibanov OM; Chaudhary T; Rives V
Future Oncol; 2023 Apr; 19(11):789-810. PubMed ID: 37170899
[TBL] [Abstract] [Full Text] [Related]
8. [Second allogeneic (update). Guidelines from the Francophone Society of bone Marrow Transplantation and Cellular Therapy (SFGM-TC)].
Yafour N; Couturier MA; Borel C; Charbonnier A; Coman T; Fayard A; Masouridi-Levrat S; Yakoub-Agha I; Roy J
Bull Cancer; 2024 Feb; 111(2S):S29-S39. PubMed ID: 37045732
[TBL] [Abstract] [Full Text] [Related]
9. Conventional chondrosarcoma of the rib cage and sternum: clinicopathological and molecular analysis of 27 patients treated at a single institution.
Abdulfatah E; Rottmann D; Morag Y; Pantanowitz L; Udager AM; Hao W; Lucas DR
Hum Pathol; 2023 Jun; 136():63-74. PubMed ID: 37019410
[TBL] [Abstract] [Full Text] [Related]
10. Clinical utility of genomic profiling of AML using paraffin-embedded bone marrow clots: HM-SCREEN-Japan 01.
Hosono N; Chi S; Yamauchi T; Fukushima K; Shibayama H; Katagiri S; Gotoh A; Eguchi M; Morishita T; Ogasawara R; Kondo T; Yanada M; Yamamoto K; Kobayashi T; Kuroda J; Usuki K; Utsu Y; Yoshimitsu M; Ishitsuka K; Ono T; Takahashi N; Iyama S; Kojima K; Nakamura Y; Fukuhara S; Izutsu K; Abutani H; Yamauchi N; Yuda J; Minami Y;
Cancer Sci; 2023 May; 114(5):2098-2108. PubMed ID: 36793248
[TBL] [Abstract] [Full Text] [Related]
11. Does PARP Inhibition Sensitize Chondrosarcoma Cell Lines to Chemotherapy or Radiotherapy? Results From a Three-dimensional Spheroid Cell Model.
Palubeckaitė I; Venneker S; van den Akker BEWM; Briaire-de Bruijn IH; Boveé JVMG
Clin Orthop Relat Res; 2023 Mar; 481(3):608-619. PubMed ID: 36729612
[TBL] [Abstract] [Full Text] [Related]
12. Biology and Management of High-Grade Chondrosarcoma: An Update on Targets and treatment Options.
Tlemsani C; Larousserie F; De Percin S; Audard V; Hadjadj D; Chen J; Biau D; Anract P; Terris B; Goldwasser F; Pasmant E; Boudou-Rouquette P
Int J Mol Sci; 2023 Jan; 24(2):. PubMed ID: 36674874
[TBL] [Abstract] [Full Text] [Related]
13. Effects of cancer-associated point mutations on the structure, function, and stability of isocitrate dehydrogenase 2.
Chen X; Yang P; Qiao Y; Ye F; Wang Z; Xu M; Han X; Song L; Wu Y; Ou WB
Sci Rep; 2022 Nov; 12(1):18830. PubMed ID: 36335201
[TBL] [Abstract] [Full Text] [Related]
14. Accelerated and blast phase myeloproliferative neoplasms.
Saliba AN; Gangat N
Best Pract Res Clin Haematol; 2022 Jun; 35(2):101379. PubMed ID: 36333070
[TBL] [Abstract] [Full Text] [Related]
15. Natural Coevolution of Tumor and Immunoenvironment in Glioblastoma.
Wu L; Wu W; Zhang J; Zhao Z; Li L; Zhu M; Wu M; Wu F; Zhou F; Du Y; Chai RC; Zhang W; Qiu X; Liu Q; Wang Z; Li J; Li K; Chen A; Jiang Y; Xiao X; Zou H; Srivastava R; Zhang T; Cai Y; Liang Y; Huang B; Zhang R; Lin F; Hu L; Wang X; Qian X; Lv S; Hu B; Zheng S; Hu Z; Shen H; You Y; Verhaak RGW; Jiang T; Wang Q
Cancer Discov; 2022 Dec; 12(12):2820-2837. PubMed ID: 36122307
[TBL] [Abstract] [Full Text] [Related]
16. Impact of idh1 and idh2 mutational subgroups in AML patients after allogeneic stem cell transplantation.
Kunadt D; Stasik S; Metzeler KH; Röllig C; Schliemann C; Greif PA; Spiekermann K; Rothenberg-Thurley M; Krug U; Braess J; Krämer A; Hochhaus A; Scholl S; Hilgendorf I; Brümmendorf TH; Jost E; Steffen B; Bug G; Einsele H; Görlich D; Sauerland C; Schäfer-Eckart K; Krause SW; Hänel M; Hanoun M; Kaufmann M; Wörmann B; Kramer M; Sockel K; Egger-Heidrich K; Herold T; Ehninger G; Burchert A; Platzbecker U; Berdel WE; Müller-Tidow C; Hiddemann W; Serve H; Stelljes M; Baldus CD; Neubauer A; Schetelig J; Thiede C; Bornhäuser M; Middeke JM; Stölzel F;
J Hematol Oncol; 2022 Sep; 15(1):126. PubMed ID: 36064577
[TBL] [Abstract] [Full Text] [Related]
17. A genetic model for central chondrosarcoma evolution correlates with patient outcome.
Cross W; Lyskjær I; Lesluyes T; Hargreaves S; Strobl AC; Davies C; Waise S; Hames-Fathi S; Oukrif D; Ye H; Amary F; Tirabosco R; Gerrand C; Baker T; Barnes D; Steele C; Alexandrov L; Bond G; ; Cool P; Pillay N; Van Loo P; Flanagan AM
Genome Med; 2022 Aug; 14(1):99. PubMed ID: 36042521
[TBL] [Abstract] [Full Text] [Related]
18. Targeted therapy with the mutant idh2 inhibitor enasidenib for high-risk idh2-mutant myelodysplastic syndrome.
DiNardo CD; Venugopal S; Lachowiez C; Takahashi K; Loghavi S; Montalban-Bravo G; Wang X; Carraway H; Sekeres M; Sukkur A; Hammond D; Chien K; Maiti A; Masarova L; Sasaki K; Alvarado Y; Kadia T; Short NJ; Daver N; Borthakur G; Ravandi F; Kantarjian HM; Patel B; Dezern A; Roboz G; Garcia-Manero G
Blood Adv; 2023 Jun; 7(11):2378-2387. PubMed ID: 35973199
[TBL] [Abstract] [Full Text] [Related]
19. Maffucci syndrome complicated by giant chondrosarcoma in the left ankle with an idh1 R132C mutation: a case report.
Lv H; Jiang H; Zhang M; Luo H; Hong Z; Yang H; Xu W; Shen B; Zhang W; Qiu H; Zhu R
World J Surg Oncol; 2022 Jun; 20(1):218. PubMed ID: 35765075
[TBL] [Abstract] [Full Text] [Related]
20. Novel Radioiodinated and Radiofluorinated Analogues of FT-2102 for SPECT or PET Imaging of midh1 Mutant Tumours.
Weber V; Arnaud L; Dukic-Stefanovic S; Wenzel B; Roux V; Chezal JM; Lai TH; Teodoro R; Kopka K; Miot-Noirault E; Deuther-Conrad W; Maisonial-Besset A
Molecules; 2022 Jun; 27(12):. PubMed ID: 35744895
[TBL] [Abstract] [Full Text] [Related]
[Next]
